New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Check out this training for the full story!
Christopher  Gibson net worth and biography

Christopher Gibson Biography and Net Worth

Christopher Gibson, Ph.D., is our co-founder, Chief Executive Officer since the company’s founding in November 2013. Dr. Gibson was also Chairman of our Board from the company’s founding until he asked, with the support of the rest of the Board, for Dr. R. Martin Chavez to accept a position of Chairman in January 2021.

Previously, Dr. Gibson was an M.D./Ph.D. student at the University of Utah. After obtaining his Ph.D., he withdrew from medical school to found Recursion. He has undergraduate degrees in bioengineering (B.S.) and managerial studies (B.A.) Rice University. He has served as a Founding Chairman of the Board of BioHive (the Utah life science collective and branding effort, composed of therapeutics, diagnostics, medical device and health IT companies, along with the companies that support them and the public sector) since November 2020. He also serves as a Board member of BioUtah (the Utah life science industry association) since January 2019, Board member of the Recursion Foundation (our not-for-profit entity seeking to promote corporate social responsibility) since November 2019, through which he is on the Board of Altitude Lab (an incubator/accelerator focused on creating the next generation of diverse biotech founder in Utah) since July 2020.

Dr. Gibson has also served on the Cures Acceleration Network Review Board since September 2020. Dr. Gibson is co-author of more than a dozen peer-reviewed studies in a variety of journals including Nature, Nature Protocols, Circulation, the Journal of Clinical Investigation, Molecular Pharmaceutics, PloS One, and Diabetes. Our Board believes Dr. Gibson is qualified to serve on our Board because of his scientific and technical background and his knowledge and perspective of the Company.

What is Christopher Gibson's net worth?

The estimated net worth of Christopher Gibson is at least $6.01 million as of December 6th, 2023. Dr. Gibson owns 791,328 shares of Recursion Pharmaceuticals stock worth more than $6,014,093 as of December 10th. This net worth estimate does not reflect any other investments that Dr. Gibson may own. Additionally, Dr. Gibson receives an annual salary of $695,180.00 as CEO at Recursion Pharmaceuticals. Learn More about Christopher Gibson's net worth.

How old is Christopher Gibson?

Dr. Gibson is currently 40 years old. There are 3 older executives and no younger executives at Recursion Pharmaceuticals. Learn More on Christopher Gibson's age.

What is Christopher Gibson's salary?

As the CEO of Recursion Pharmaceuticals, Inc., Dr. Gibson earns $695,180.00 per year. Learn More on Christopher Gibson's salary.

How do I contact Christopher Gibson?

The corporate mailing address for Dr. Gibson and other Recursion Pharmaceuticals executives is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. Recursion Pharmaceuticals can also be reached via phone at 385-269-0203 and via email at [email protected]. Learn More on Christopher Gibson's contact information.

Has Christopher Gibson been buying or selling shares of Recursion Pharmaceuticals?

During the last quarter, Christopher Gibson has sold $1,072,554.35 in shares of Recursion Pharmaceuticals stock. Most recently, Christopher Gibson sold 59,829 shares of the business's stock in a transaction on Wednesday, December 6th. The shares were sold at an average price of $7.49, for a transaction totalling $448,119.21. Following the completion of the sale, the chief executive officer now directly owns 791,328 shares of the company's stock, valued at $5,927,046.72. Learn More on Christopher Gibson's trading history.

Who are Recursion Pharmaceuticals' active insiders?

Recursion Pharmaceuticals' insider roster includes Blake Borgeson (Director), Christopher Gibson (CEO), Tina Larson (COO), and Dean Li (Director). Learn More on Recursion Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Recursion Pharmaceuticals?

In the last year, Recursion Pharmaceuticals insiders bought shares 10 times. They purchased a total of 581,017 shares worth more than $4,440,853.30. In the last year, insiders at the sold shares 64 times. They sold a total of 1,130,891 shares worth more than $9,893,086.48. The most recent insider tranaction occured on December, 6th when CEO Christopher Gibson sold 59,829 shares worth more than $448,119.21. Insiders at Recursion Pharmaceuticals own 20.0% of the company. Learn More about insider trades at Recursion Pharmaceuticals.

Information on this page was last updated on 12/6/2023.

Christopher Gibson Insider Trading History at Recursion Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/6/2023Sell59,829$7.49$448,119.21791,328View SEC Filing Icon  
11/1/2023Sell37,177$5.20$193,320.40836,820View SEC Filing Icon  
10/4/2023Sell59,794$7.21$431,114.74842,747View SEC Filing Icon  
9/6/2023Sell33,765$8.78$296,456.70871,291View SEC Filing Icon  
8/2/2023Sell65,015$13.04$847,795.60890,719View SEC Filing Icon  
7/12/2023Sell31,818$13.14$418,088.52915,810View SEC Filing Icon  
6/7/2023Sell56,436$9.05$510,745.80916,378View SEC Filing Icon  
5/3/2023Sell33,073$4.71$155,773.83953,225View SEC Filing Icon  
4/5/2023Sell13,327$6.46$86,092.42946,710View SEC Filing Icon  
3/8/2023Sell70,890$8.10$574,209.00963,787View SEC Filing Icon  
3/2/2023Sell18,500$7.92$146,520.00940,927View SEC Filing Icon  
1/5/2023Sell18,500$7.39$136,715.00525,805View SEC Filing Icon  
12/1/2022Sell37,210$9.02$335,634.20582,805View SEC Filing Icon  
11/3/2022Sell36,693$10.00$366,930.00576,016View SEC Filing Icon  
10/6/2022Sell36,053$11.58$417,493.74562,959View SEC Filing Icon  
8/4/2022Sell36,825$9.49$349,469.25541,829View SEC Filing Icon  
7/7/2022Sell37,114$9.05$335,881.70528,904View SEC Filing Icon  
6/2/2022Sell39,690$6.09$241,712.10516,268View SEC Filing Icon  
5/4/2022Sell31,830$6.49$206,576.70511,972View SEC Filing Icon  
4/28/2022Sell37,605$6.09$229,014.45469,608View SEC Filing Icon  
4/21/2022Sell37,155$6.31$234,448.05420,146View SEC Filing Icon  
4/18/2022Sell35,836$6.84$245,118.24394,791View SEC Filing Icon  
4/14/2022Sell34,517$7.56$260,948.52368,117View SEC Filing Icon  
4/7/2022Sell36,718$6.54$240,135.72314,534View SEC Filing Icon  
4/5/2022Sell34,472$7.43$256,126.96288,742View SEC Filing Icon  
3/14/2022Sell230,000$6.28$1,444,400.00View SEC Filing Icon  
3/11/2022Sell100,000$6.95$695,000.00View SEC Filing Icon  
3/7/2022Sell300,000$7.30$2,190,000.00View SEC Filing Icon  
2/22/2022Sell100,000$10.22$1,022,000.00View SEC Filing Icon  
1/31/2022Sell19,858$11.73$232,934.34View SEC Filing Icon  
1/13/2022Sell87,000$14.33$1,246,710.00View SEC Filing Icon  
12/16/2021Sell200$20.00$4,000.00View SEC Filing Icon  
12/13/2021Sell100$20.02$2,002.00View SEC Filing Icon  
12/9/2021Sell1,086$20.01$21,730.86View SEC Filing Icon  
12/7/2021Sell3,125$20.51$64,093.75View SEC Filing Icon  
See Full Table

Christopher Gibson Buying and Selling Activity at Recursion Pharmaceuticals

This chart shows Christopher Gibson's buying and selling at Recursion Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Recursion Pharmaceuticals Company Overview

Recursion Pharmaceuticals logo
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Read More

Today's Range

Now: $7.60
Low: $7.27
High: $7.68

50 Day Range

MA: $6.45
Low: $5.09
High: $7.60

2 Week Range

Now: $7.60
Low: $4.54
High: $16.75


5,745,171 shs

Average Volume

4,919,342 shs

Market Capitalization

$1.65 billion

P/E Ratio


Dividend Yield